Cardlytics (NASDAQ:CDLX) Upgraded at Craig Hallum

Craig Hallum upgraded shares of Cardlytics (NASDAQ:CDLX) from a hold rating to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

Several other brokerages have also commented on CDLX. Northland Securities lowered shares of Cardlytics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Evercore ISI started coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a report on Thursday. Finally, Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $4.00 to $3.50 in a report on Thursday, August 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.92.

Cardlytics Price Performance

CDLX opened at $4.37 on Wednesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a market capitalization of $217.80 million, a PE ratio of -1.14 and a beta of 1.61. The stock’s 50 day moving average price is $3.69 and its 200-day moving average price is $6.70. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The business had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The company’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.57) EPS. On average, equities research analysts predict that Cardlytics will post -1.72 EPS for the current year.

Insider Activity at Cardlytics

In related news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Cardlytics news, Director Scott A. Hill bought 40,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $3.58 per share, with a total value of $143,200.00. Following the transaction, the director now owns 40,000 shares in the company, valued at $143,200. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,573 shares of company stock valued at $151,612. 4.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Cardlytics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after buying an additional 57,805 shares during the last quarter. Marshall Wace LLP increased its position in Cardlytics by 6.8% during the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after acquiring an additional 52,081 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after acquiring an additional 354,474 shares during the period. Renaissance Technologies LLC boosted its position in Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares during the last quarter. Finally, Kent Lake Capital LLC purchased a new stake in shares of Cardlytics during the 1st quarter valued at about $3,622,000. Institutional investors own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.